# SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System

Study · id `cardio:ct-nct02439775` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02439775](<https://clinicaltrials.gov/study/NCT02439775>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02439775

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 337 participants.

## Technical summary

Registry record NCT02439775. Randomized; single masking; primary purpose treatment. Start 2015-07-22 (actual); primary completion 2022-08-18 (actual). Results posted on 2023-09-15.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 337 participants (enrolled count; ClinicalTrials.gov record NCT02439775, source copy `cardio:ctgov-nct02439775-2026-07-30`, retrieved 2026-10-26)
- Started: 2015-07-22 (actual) (ClinicalTrials.gov record NCT02439775, source copy `cardio:ctgov-nct02439775-2026-07-30`, retrieved 2026-10-26)
- Primary completion: 2022-08-18 (actual) (ClinicalTrials.gov record NCT02439775, source copy `cardio:ctgov-nct02439775-2026-07-30`, retrieved 2026-10-26)
- Completion: 2025-08-14 (actual) (ClinicalTrials.gov record NCT02439775, source copy `cardio:ctgov-nct02439775-2026-07-30`, retrieved 2026-10-26)
- Results first posted: 2023-09-15 (ClinicalTrials.gov record NCT02439775, source copy `cardio:ctgov-nct02439775-2026-07-30`, retrieved 2026-10-26)
- Countries: United States; Australia; Austria; Canada; France; Germany; Greece; Ireland; Japan; United Kingdom (ClinicalTrials.gov record NCT02439775, source copy `cardio:ctgov-nct02439775-2026-07-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02439775-2026-07-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System
- Condition: Hypertension
- Condition: Vascular Diseases
- Condition: Cardiovascular Diseases
- Intervention (Device): Symplicity Spyral™ multi-electrode renal denervation system
- Intervention (Procedure): Sham Procedure
- Lead sponsor: Medtronic Vascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Medtronic Vascular (`cardio:org-medtronic-vascular`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications (`cardio:pubmed-37914510`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED (`cardio:pubmed-38314554`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED Trial (`cardio:pubmed-40391448`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MED (`cardio:pubmed-42294771`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b3c100312a8a8c4be4e6bd9a0735b9b1fa2b8a384fc9f43f904f4ec56eb66fa7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
